Peter Homberg is a leading authority in the legal frameworks surrounding life sciences and the medical cannabis industry in Germany and Europe. With deep expertise in corporate law, M&A, and intellectual property, he advises a broad spectrum of clients—from emerging biotech start-ups to multinational pharmaceutical corporations—on navigating high-stakes transactions and regulatory complexity.

His practice focuses on sectors such as pharmaceuticals, diagnostics, medical devices, and biotechnology, with a particular specialization in medical cannabis. Peter supports clients through cross-border M&A deals, licensing and R&D agreements, IP strategies, and compliance structures tailored to highly regulated industries. His extensive experience in Southeast Asia adds a global dimension to his transactional work.

Over the years, Peter has received numerous accolades for his contributions to the legal profession. Amongst others, he has been recognized by The Legal 500 for his excellence in healthcare and life sciences law and has been named a leading expert by Leaders in Law. His standing as a thought leader is reflected not only in these rankings, but also in his frequent invitations to speak at international conferences and his authorship of numerous articles on corporate, IP, and regulatory topics.

In 2025 alone, Peter played a pivotal role in securing major recognition for gunnercooke: the firm was listed among ICBC’s Top Cannabis Companies of the Year, and named Leading Law Firm for Cannabis by the Legal Industry Review. These achievements reflect both his personal leadership and the strength of his legal practice.

Peter is an active member of the Pharma-Lizenz-Club Deutschland e. V. and the Branchenverband Cannabiswirtschaft e. V. (BvCW), and continues to help shape legal standards and policy within the cannabis and life sciences industries in Germany and beyond.

His clients include, among others:

Start-ups
Medium-sized companies
Listed companies
Nationally and internationally operating groups of companies
Financial investors
Strategic investors